OTTMUSG00000019786 Inhibitors
The inhibition of the protein LOC100041759 involves a series of chemical inhibitors that target specific pathways and enzymes crucial for its activation and function. Staurosporine, as a kinase inhibitor, plays a pivotal role in this context by inhibiting protein kinases essential for the phosphorylation and activation of many proteins, including LOC100041759. This inhibition disrupts the phosphorylation-dependent activation processes of LOC100041759, rendering it functionally inactive. Similarly, LY294002, by targeting phosphoinositide 3-kinases (PI3K), hinders the activation of the AKT signaling pathway, which is integral to the function of LOC100041759. The reduced activation of AKT, a downstream effect of PI3K inhibition, subsequently leads to the functional inhibition of LOC100041759.
Furthermore, inhibitors like Rapamycin, PD98059, SP600125, SB203580, U0126, Wortmannin, Dasatinib, Lapatinib, Sorafenib, and AZD6244 each play a distinct but critical role in modulating the pathways that regulate LOC100041759. Rapamycin, by inhibiting mTOR, affects the regulation of protein synthesis and cell growth, pathways that are crucial for the regulation of LOC100041759. PD98059 and U0126, by inhibiting MEK, disrupt the MAPK/ERK signaling, a key pathway in the regulation and activation of LOC100041759. Similarly, SP600125 and SB203580 inhibit the JNK and p38 MAP kinases, respectively, both part of the MAPK signaling pathway, thereby impeding the activation process of LOC100041759. Wortmannin, with its potent inhibitory action on PI3K, and Dasatinib, as a Src family kinase inhibitor, disrupt the signaling pathways regulating LOC100041759, leading to its inhibition. Lapatinib, targeting the tyrosine kinase activities of HER2 and EGFR, and Sorafenib, targeting multiple kinases in the MAPK pathway, both contribute to the disruption of signaling pathways vital for LOC100041759. AZD6244, by inhibiting MEK1/2, further ensures the disruption of the MAPK/ERK signaling pathway, culminating in the inhibition of LOC100041759. Each of these inhibitors, through their targeted action on specific kinases and pathways, ensures the effective and functional inhibition of LOC100041759, illustrating a complex network of biochemical interactions and regulatory mechanisms.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. It inhibits the phosphorylation activity of kinases which is essential for the activation of many proteins, including LOC100041759. This inhibition disrupts the phosphorylation-dependent activation processes of LOC100041759, leading to its functional inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 specifically inhibits phosphoinositide 3-kinases (PI3K), which play a critical role in the activation of the AKT signaling pathway. LOC100041759 is involved in this pathway; thus, the inhibition of PI3K by LY294002 can lead to the reduced activation of AKT, subsequently inhibiting the functional activity of LOC100041759. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. Since mTOR is involved in the regulation of protein synthesis and cell growth, its inhibition can lead to the downregulation of several proteins, including LOC100041759, which is regulated by the mTOR pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a specific inhibitor of MEK, which is involved in the MAPK/ERK pathway. LOC100041759 is known to be regulated by this pathway. Inhibition of MEK by PD98059 can impede the MAPK/ERK signaling, leading to the inhibition of LOC100041759 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK (c-Jun N-terminal Kinase), a protein kinase that is part of the MAPK pathway. LOC100041759 is regulated by the MAPK pathway, so inhibiting JNK with SP600125 can hinder the pathway’s role in activating LOC100041759. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 specifically inhibits p38 MAP kinase, which is a part of the MAPK signaling pathway. Since LOC100041759 is regulated by the MAPK pathway, inhibition of p38 by SB203580 can impede the activation process of LOC100041759. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, enzymes in the MAPK/ERK pathway. By inhibiting MEK1/2, U0126 disrupts the MAPK/ERK pathway, which is crucial for the regulation and activation of LOC100041759, leading to its inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K). LOC100041759 is part of the PI3K-AKT signaling pathway, and thus the inhibition of PI3K by Wortmannin leads to the disruption of this pathway, inhibiting LOC100041759. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. Src kinases are involved in various signaling pathways, including those regulating LOC100041759. By inhibiting Src kinases, Dasatinib disrupts these signaling pathways, leading to the inhibition of LOC100041759. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib inhibits the tyrosine kinase activities of HER2 and EGFR, which are involved in signaling pathways that regulate LOC100041759. Inhibition of these kinases by Lapatinib leads to the disruption of these pathways, inhibiting LOC100041759. | ||||||